Immix Biopharma Stock Alpha and Beta Analysis
| IMMX Stock | USD 1.68 0.14 7.69% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Immix Biopharma. It also helps investors analyze the systematic and unsystematic risks associated with investing in Immix Biopharma over a specified time horizon. Remember, high Immix Biopharma's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Immix Biopharma's market risk premium analysis include:
Beta 1.26 | Alpha (0.45) | Risk 5.54 | Sharpe Ratio (0.04) | Expected Return (0.25) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Immix |
Immix Biopharma Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Immix Biopharma market risk premium is the additional return an investor will receive from holding Immix Biopharma long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Immix Biopharma. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Immix Biopharma's performance over market.| α | -0.45 | β | 1.26 |
Immix Biopharma expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Immix Biopharma's Buy-and-hold return. Our buy-and-hold chart shows how Immix Biopharma performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Immix Biopharma Market Price Analysis
Market price analysis indicators help investors to evaluate how Immix Biopharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Immix Biopharma shares will generate the highest return on investment. By understating and applying Immix Biopharma stock market price indicators, traders can identify Immix Biopharma position entry and exit signals to maximize returns.
Immix Biopharma Return and Market Media
The median price of Immix Biopharma for the period between Sat, Aug 24, 2024 and Fri, Nov 22, 2024 is 1.68 with a coefficient of variation of 13.36. The daily time series for the period is distributed with a sample standard deviation of 0.23, arithmetic mean of 1.73, and mean deviation of 0.18. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Insider Spends US52k Buying More Shares In Immix Biopharma | 08/29/2024 |
2 | Immix CAR-T Therapy IND Cleared by FDA, Stock Down - MSN | 09/23/2024 |
3 | Acquisition by Morris Gabriel S of 4500 shares of Immix Biopharma at 2.2315 subject to Rule 16b-3 | 09/27/2024 |
4 | Acquisition by Buchan Jane of 1332 shares of Immix Biopharma subject to Rule 16b-3 | 10/18/2024 |
5 | Immix Biopharma Posts Quarterly Earnings Results, Misses Expectations By 0.08 EPS | 11/14/2024 |
About Immix Biopharma Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Immix or other stocks. Alpha measures the amount that position in Immix Biopharma has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2010 | 2023 | 2024 (projected) | Gross Profit Margin | 1.0 | 0.9 | 0.8 | Net Profit Margin | 0.0919 | 0.0827 | 0.0735 |
Immix Biopharma Upcoming Company Events
As portrayed in its financial statements, the presentation of Immix Biopharma's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Immix Biopharma's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Immix Biopharma's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Immix Biopharma. Please utilize our Beneish M Score to check the likelihood of Immix Biopharma's management manipulating its earnings.
| 25th of March 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 25th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Immix Biopharma
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Immix Stock Analysis
When running Immix Biopharma's price analysis, check to measure Immix Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immix Biopharma is operating at the current time. Most of Immix Biopharma's value examination focuses on studying past and present price action to predict the probability of Immix Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immix Biopharma's price. Additionally, you may evaluate how the addition of Immix Biopharma to your portfolios can decrease your overall portfolio volatility.